Clinical Trial

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Study acronym: PNOC016
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 35 amendments
This ClinicalTrials.gov record has been amended 35 times since 2019-03-26; most recent amendment 2025-07-08.
Status change: Recruiting → Active, Not Recruiting 2022-08-16
Status change: Not Yet Recruiting → Recruiting 2019-05-29
Trial Details
NCT Number NCT03893487
Lead Sponsor Sabine Mueller, MD, PhD
Collaborators: Pediatric Neuro-Oncology Consortium, Cannonball Kids' Cancer Foundation, Curis, Inc.
Conditions Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
Enrollment 30 participants
Start Date 2019-08-07
Primary Completion 2022-10-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-11